Thrombosis with thrombocytopenia syndrome (TTS) & COVID-19 AstraZeneca

In light of the change in recommendation regarding the administration of COVID-19 AstraZeneca in those under 50 years, we are excited to be hosting a special clinical feature event on Thrombosis with thrombocytopenia syndrome (TTS) & COVID-19 AstraZeneca. Our panel will be giving background on what this new syndrome is and explore its association with the vaccine. We will also discuss the importance of a risk-versus-benefit assessment and how this new recommendation will impact confidence in the vaccine rollout.

Event details:
Date: Tuesday 20th April 2021
Time: 7pm – 8:30pm AEDT

WordPress Tables Plugin


Dr Daryl Cheng
MBBS, MPH, FRACP Medical Advisor, Melbourne Vaccine Education Centre

Dr Cheng is a general paediatrician who works at The Royal Children’s Hospital and Monash Children’s Hospital. He is a Senior Research Fellow at Murdoch Children’s Research Institute. He has special interests in immunisation, education and health informatics.

Professor Jim Buttery
Head of Health Informatics, Epidemiology and Signal Detection, SAEFVIC (Murdoch Children’s Research Institute)    

Prof Jim Buttery is a paediatric infectious diseases physician and vaccinologist. He is the inaugural Professor of Child Health Informatics at the University of Melbourne. He is Head of Health Informatics, Epidemiology and Signal detection at SAEFVIC (MCRI) and Chief Clinical Research Information Officer & Infectious Diseases Physician at The Royal Children’s Hospital. Prof Buttery also serves as a member of the Strategic Priority Group of WHO Global Vaccine Safety Initiative, the Australian Medical Services Advisory Committee, and the TGA Advisory Committee on Vaccines.

Professor Paul Monagle
Professor of Paediatrics, University of Melbourne 

Prof Paul Monagle is a past chair of the paediatric/perinatal Scientific Subcommittee of ISTH; leader ACCP /ASH antithrombotic guidelines in children for almost 2 decades; member of PODIUM, PEACE initiatives driving research in complex coagulopathies of childhood, and a key player in the Einstein Junior studies of rivaroxaban. Co-author of multiple textbooks; 40 chapters in major international textbooks; over 300 publications, with over 10000 citations.

Paul has long term interests in reference ranges and normative data, epidemiology of thrombosis in children, paediatric stroke, age related changes in anticoagulant use and monitoring and anticoagulant clinical trials.  Over the last 12 months he has been actively involved in research related to SarsCoV-2 and clotting.

Associate Professor Nigel Crawford
Director, SAEFVIC (Murdoch Children’s Research Institute)    

Associate Professor Crawford is a vaccinologist and consultant paediatrician, Director of SAEFVIC (Murdoch Children’s Research Institute) and Head of Immunisation Services at The Royal Children’s Hospital. He is an expert in the vaccination of special risk groups (e.g. immunosuppressed patients), a member of ATAGI and the co-lead of AEFI-CAN.